
Is It PCOS, or Something That Looks Like PCOS?
It usually looks like this: a handful of small follicles on one ovary, a testosterone value flagged slightly high, and a diagnosis of PCOS written on the after-visit summary before anyone asked why the cycles had actually stopped. No thyroid panel. No prolactin. No morning hormone drawn to rule out an adrenal cause. No question about a year of eating less and training harder. This happens constantly, and it matters, because the treatment for polycystic ovary syndrome is often the wrong treatment for whatever is really going on.
Can something else really look exactly like PCOS?
Yes. Several distinct conditions — thyroid disease, high prolactin, non-classic congenital adrenal hyperplasia, hypothalamic amenorrhoea, Cushing's syndrome, and a handful of others — can each produce irregular or absent periods, acne or excess hair growth, and follicle-studded ovaries on ultrasound, the same three features used to diagnose PCOS. PCOS is what doctors call a diagnosis of exclusion: it is only supposed to be given after those other causes have been checked for and ruled out, and that exclusion step is the one most often skipped.
What are the actual Rotterdam criteria, and what part keeps getting skipped?
The Rotterdam criteria, first published by the ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group in 2004, require two of three features: irregular or absent ovulation, clinical or biochemical signs of excess androgen (hirsutism, acne, or an elevated testosterone), and polycystic ovarian morphology on ultrasound. Two out of three sounds simple, and that simplicity is exactly what causes trouble, because the criteria carry a fourth requirement that never makes it into a five-minute visit: the diagnosis is valid only after other conditions that can cause the same picture have been excluded. Our detailed walk-through of how the Rotterdam criteria are meant to be applied covers the three features themselves; this post is about the step that comes before you get to count them.
The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, led by Helena Teede's international panel and endorsed across reproductive endocrinology societies, reaffirmed that exclusion requirement and added two specific refinements. First, anti-Müllerian hormone (AMH) can now be used as an alternative to ultrasound for assessing ovarian morphology in adults, which helps because a transvaginal scan is not always available or appropriate. Second, ultrasound (and, by extension, AMH-based morphology assessment) should not be used to diagnose PCOS within about eight years of a girl's first period, because multifollicular ovaries are a normal feature of adolescent ovarian development and will resolve on their own in many teenagers who do not have PCOS at all.
Why would a doctor diagnose PCOS without ruling anything else out?
Volume and habit, mostly. A short visit, a slightly elevated testosterone, and follicles on a scan match the pattern clinicians see most often, and PCOS is common enough that it becomes the default answer. The 2013 Endocrine Society clinical practice guideline on PCOS diagnosis is explicit that the workup should include, at minimum, thyroid-stimulating hormone and prolactin in every patient, with 17-hydroxyprogesterone added for anyone with hirsutism, because skipping that short panel is how the wrong diagnosis gets made. None of this means the original diagnosis was made in bad faith. It means a two-out-of-three checklist got applied without the fourth item, and the fix is not confrontation — it is a specific, short list of tests.
What conditions get mistaken for PCOS most often, and what actually tells them apart?
Each of the following can produce irregular cycles, androgen signs, or PCOS-looking ovaries, and each has a specific test or history detail that separates it from true PCOS.
Hypothalamic amenorrhoea (HA): low or low-normal LH and FSH, low oestradiol, and no hyperandrogenism, in the setting of low energy availability from restrictive eating, high training load, or significant stress. The trap: ovaries in HA can look multifollicular on ultrasound, resembling PCOS morphology, which is why morphology alone should never carry the diagnosis. The Endocrine Society's 2017 guideline on functional hypothalamic amenorrhoea lays out this picture, and a 2022 retrospective comparison found that a meaningful share of women labelled with PCOS phenotype D (ovulatory dysfunction plus morphology, without androgen excess) were better explained by HA once energy status and gonadotropin patterns were reviewed.
Thyroid disease: both hypothyroidism and hyperthyroidism disrupt ovulation and cycle length. A single TSH, drawn in the morning, is the screening test, and it is the one most often left out of an initial workup. We cover the broader connection in how thyroid dysfunction affects fertility.
Hyperprolactinaemia and prolactinoma: elevated prolactin suppresses gonadotropin pulsing and stops ovulation, sometimes with milky nipple discharge, sometimes with none. A fasting morning prolactin, and imaging if it is persistently high, is the separating step, per the Endocrine Society's 2011 guideline on hyperprolactinaemia.
Non-classic congenital adrenal hyperplasia (NCAH): the single most-missed mimic. NCAH is a mild, later-onset, genetic form of 21-hydroxylase deficiency that produces excess adrenal androgens and can look identical to PCOS — irregular cycles, acne, hirsutism, sometimes PCOS-like ovaries. It is separated by a 17-hydroxyprogesterone level drawn in the early follicular phase, in the morning, before 9 a.m. if possible, since the hormone follows a diurnal and cyclical pattern that produces false negatives at the wrong time. A 2017 review in Human Reproduction Update notes NCAH is found in a meaningful minority of women initially worked up for hyperandrogenism, which is why an earlier clinician nicknamed it "the great pretender." A normal total testosterone and DHEAS does not close this door either — we walk through which androgen labs get missed when the standard two look normal separately.
Cushing's syndrome: excess cortisol from any source produces irregular cycles, weight gain (often central), and androgen excess. Distinguishing features include easy bruising, wide purple striae, muscle weakness, and a characteristic pattern of fat redistribution; screening uses a late-night salivary cortisol, an overnight dexamethasone suppression test, or 24-hour urinary free cortisol, never a single random blood draw.
Androgen-secreting tumour (ovarian or adrenal): the clue is speed. Rapid-onset or rapidly worsening hirsutism, deepening of the voice, clitoral enlargement, or a very markedly elevated total testosterone (well beyond typical PCOS ranges) over a period of months, rather than years, should prompt imaging rather than a PCOS label.
Acromegaly: growth hormone excess can produce irregular cycles and PCOS-like ovarian morphology, and it is under-recognised because the physical changes (enlarging hands, feet, and jaw) develop slowly. A 2023 retrospective study of 97 reproductive-aged women with acromegaly found a substantial share had been diagnosed with PCOS first, sometimes years earlier; an earlier study of women with active acromegaly documented polycystic ovarian morphology tied directly to the growth hormone excess.
Primary ovarian insufficiency (POI): irregular or absent periods before age 40, but the hormone direction is the opposite of PCOS — FSH is high and oestradiol is low, signalling a declining, not overactive, follicle pool, alongside hot flashes and vaginal dryness more typical of a much older reproductive stage.
Drug-induced anovulation: valproate (used for epilepsy and some mood disorders) is associated with PCOS-like features including weight gain, hyperandrogenism, and polycystic ovarian morphology in multiple studies; exogenous androgens (including some compounded hormone products) and certain progestin-only methods can also disrupt cycles and skin symptoms in ways that mimic PCOS. A full medication history belongs in every workup.
Post-pill anovulation: cycles can take several months to resume a regular pattern after stopping hormonal contraception, and testosterone and AMH readings taken on or shortly after combined hormonal contraception are unreliable, which is a separate problem from true post-pill anovulation but gets confused with it constantly.
Obesity and insulin resistance without PCOS: excess weight and insulin resistance can cause irregular cycles and mild androgen elevation on their own, without meeting full PCOS criteria, which is one more reason morphology or one lab value alone should never close the case.
Idiopathic hirsutism: excess hair growth with normal ovulation, normal androgen levels, and normal ovaries — a real, separate diagnosis, not "hirsutism from PCOS with normal labs." A 2012 consensus statement from the Androgen Excess and PCOS Society lays out how this diagnosis is reached by exclusion, the same logic PCOS itself is supposed to follow.
Why does the specific label actually change what you'd be told to do?
Because the standard PCOS toolkit assumes a specific physiology, and that toolkit is the wrong tool if the underlying problem is different. Letrozole, metformin, and inositol strategies used for PCOS-related ovulatory dysfunction assume a hormonal environment where the ovaries are present, follicle-rich, and simply not releasing an egg on schedule because of insulin resistance and elevated androgens. A woman with hypothalamic amenorrhoea has a different problem: her hypothalamus has down-regulated reproductive signalling because her body lacks the energy to support it, and the treatment is restoring energy availability, not stimulating ovulation in a system paused for a physiological reason. Reversing that sequence can delay the real fix by months or years. A woman with NCAH needs genetic counselling, because it is inherited, with implications for a future child's risk, not just a hormone problem to manage. Every one of these decisions — testing, medication, when to treat versus wait — belongs with her OB-GYN or reproductive endocrinologist; we are not making that call for any individual reader here.
How do doctors actually tell lean PCOS apart from hypothalamic amenorrhoea?
This is the hardest real-world call in the whole differential, because a lean woman with irregular cycles and PCOS-looking ovaries and a lean woman with HA and PCOS-looking ovaries can present almost identically on a single ultrasound. Clinicians work through it with a cluster of findings rather than one test: the LH:FSH ratio (often elevated in PCOS, low-normal or reversed in HA), AMH interpreted alongside the ovarian picture, oestradiol (low in HA, typically normal in PCOS), and the history a scan cannot show — energy intake relative to output, training volume, recent weight loss, menstrual history beyond the last few cycles, and whether hyperandrogenism is present at all, since HA does not produce excess androgen and PCOS by definition does. Readers working through the lean-body version of this question will find more in our lean PCOS breakdown, and in how exercise load and cortisol interact with ovulation, which covers the HA side of this distinction.
What if I'm still ovulating sometimes — does that rule out PCOS or something else?
Not automatically, and it is worth asking a different question than "am I ovulating." Some women with PCOS ovulate intermittently, which is its own planning problem we address directly in still ovulating with PCOS and planning for pregnancy. Intermittent ovulation with hyperandrogenism still fits the PCOS definition. Intermittent ovulation without any androgen signs, alongside a low oestradiol and a restrictive eating or training history, points toward HA instead. The presence or absence of ovulation on its own does not sort these conditions — it has to be read together with the hormone pattern and the history.
Could my irregular periods be about iron or metabolism instead of a hormone diagnosis at all?
It is worth checking before accepting any label. Iron status affects thyroid hormone conversion and can independently disrupt cycle regularity — we cover the mechanism in how low iron and ferritin affect periods — and it is a cheap, common test that is rarely included in an initial PCOS workup even though it should be. And PCOS itself is increasingly understood as a metabolic and immune condition playing out through the ovary rather than a disease that originates in the ovary; our explanation of why PCOS isn't fundamentally an ovary problem covers that reframing, which matters here because it is one more reason ovarian appearance alone was never meant to carry a diagnosis.
What should I actually ask for if I think my PCOS diagnosis was never properly worked up?
Ask for a specific panel, drawn at a specific time. In the early follicular phase (day two to five, if cycles are present), fasting, and — if you have been on hormonal contraception — after a washout period your clinician determines, ask for: TSH, prolactin, total and free testosterone, morning 17-hydroxyprogesterone, and, depending on the picture, an AMH and a fasting glucose or insulin panel. If your periods stopped rather than merely became irregular, ask whether LH, FSH, and oestradiol were checked, since a low-low-low pattern points away from PCOS entirely. You are not required to litigate this with your doctor. A calm, specific request — "given that PCOS is a diagnosis of exclusion, can we run TSH, prolactin, and a morning 17-OH progesterone before we finalize this" — is reasonable and evidence-based, and both the 2023 international guideline and the Endocrine Society's diagnostic guideline back that request. If a clinician is unwilling to revisit a label with that framing, a second opinion from a reproductive endocrinologist is a reasonable next step, not an overreaction.
Where does a clinic like yours fit once the actual diagnosis is confirmed?
Our role starts after the diagnostic question is settled, not before it. We do not run the panel above, interpret 17-hydroxyprogesterone results, or diagnose Cushing's syndrome or a tumour — that belongs entirely with your OB-GYN, reproductive endocrinologist, or endocrinologist. What East to West Fertility does, once a diagnosis is confirmed or narrowed, is build a metabolic and immune workup around whatever the correct picture turns out to be: for confirmed PCOS, that means insulin sensitivity, inflammatory markers, and the blood flow and signaling patterns covered in our 3 Fertility Dials framework; for HA, it means supporting the metabolic and nervous-system load energy deficit places on the body while medical energy-availability work happens in parallel; for NCAH or another adrenal cause, it means working alongside your physician's plan, not around it. Long Island patients frequently arrive at our Huntington office holding a PCOS diagnosis from years earlier that was never revisited, and the first useful step is often confirming the diagnosis is the right one.
What's the single most useful thing to take away from all of this?
A PCOS diagnosis made from an ultrasound and one testosterone value, without a thyroid panel, a prolactin, and — for anyone with hirsutism — a properly timed 17-hydroxyprogesterone, has not actually excluded the conditions PCOS is supposed to be diagnosed against. That does not mean the original diagnosis is wrong; for most women who meet Rotterdam's two-of-three criteria and have a normal short panel, it is exactly right. It means the label is worth confirming once, properly, especially before years of treatment go toward the wrong physiology. Whether that turns out to be classic PCOS, lean PCOS, hypothalamic amenorrhoea, NCAH, or something rarer, the path forward gets shorter once the diagnosis is actually settled instead of assumed.
This article is for general educational purposes and is not a substitute for individualized medical care. Testing, diagnosis, genetic screening and any medication decisions belong with your OB-GYN or reproductive endocrinologist, based on your own history.
East to West Fertility is a systems biology fertility clinic in Huntington, Long Island, serving patients across Long Island, NYC, and beyond. Learn more about our Metabolic & Immune Fertility Evaluation or call 631-416-4940.
References:
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome." Fertility and Sterility, 2004;81(1):19-25.
Teede HJ, Tay CT, Laven JJE, et al. "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." Journal of Clinical Endocrinology & Metabolism, 2023;108(10):2447-2469.
Legro RS, Arslanian SA, Ehrmann DA, et al. "Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology & Metabolism, 2013;98(12):4565-4592.
Gordon CM, Ackerman KE, Berga SL, et al. "Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism, 2017;102(5):1413-1439.
Beitl K, Dewailly D, Seemann R, et al. "Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis." Frontiers in Endocrinology, 2022;13:904706.
Melmed S, Casanueva FF, Hoffman AR, et al. "Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology & Metabolism, 2011;96(2):273-288.
Speiser PW, Arlt W, Auchus RJ, et al. "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism, 2018;103(11):4043-4088.
Carmina E, Dewailly D, Escobar-Morreale HF, et al. "Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women." Human Reproduction Update, 2017;23(5):580-599.
Moran C, Azziz R. "21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender." Seminars in Reproductive Medicine, 2003;21(3):295-300.
Khiyami AM, Jokar TO, Abdallah HM, et al. "Polycystic ovary syndrome preceding the diagnosis of acromegaly: a retrospective study in 97 reproductive-aged women." Reproductive Biology and Endocrinology, 2023;21(1):14. (97 women, retrospective.)
Kaltsas GA, Androulakis II, Tziveriotis K, et al. "Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly." Clinical Endocrinology, 2007;67(6):917-922.
Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C. "A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy." Epilepsy Research, 2011;97(1-2):73-82.
Escobar-Morreale HF, Carmina E, Dewailly D, et al. "Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society." Human Reproduction Update, 2012;18(2):146-170.
